Alexander Shtilbans

Director of Movement Disorder Program, HSS, Hospital for Special Surgery; Assistant Professor of Neurology Cornell University

Wednesday 4th February 2026

Panel Discussion: From Proteinopathies to Pathways: The Next Wave of Disease-Modifying Therapies in AD & PD – Beyond Aβ, Tau & α-Synuclein

8:30 am

How do we move beyond targeting amyloid, tau, and α-synuclein to intervene earlier in the disease cascade through pathways like neuroinflammation, lysosomal dysfunction, and mitochondrial stress?
What evidence is now required to prove disease modification in the clinic, and how can diagnostic, target-engagement, and progression biomarkers be aligned to make this measurable and regulatory-credible?
Where does precision neurology realistically stand today, and how far can patient subtyping and enrichment strategies go before regulatory and operational constraints take over?
When do combination and mixed-modality approaches outperform single mechanisms, and how can they be designed to deliver more durable, scalable disease-modifying impact?

Wednesday 4th February 2026

Combining Therapeutic Strategies in Parkinson’s Disease: Enhancing Efficacy Through Multi-Target Approaches

1:30 pm

Targeting multiple pathogenic mechanisms simultaneously, including mitochondrial dysfunction, oxidative stress, and protein aggregation to slow neurodegeneration more effectively than single-agent approaches
Combining neuroprotective agents in rational, mechanistically complementary regimens, creating synergistic effects against converging pathways of PD pathology to increase the likelihood of achieving true disease modification
Leveraging preclinical and translational models to evaluate multi-target strategies, optimizing combinations before clinical trials to accelerate the development of effective therapies